Eine Studie über neuartige Antikrebsmittel bei Patienten mit metastasiertem dreifach negativem Brustkrebs (BEGONIA)
Eine zweistufige, offene, multizentrische Phase-IB/II-Studie zur Bestimmung der Wirksamkeit und Sicherheit von Durvalumab (MEDI4736) + Paclitaxel und Durvalumab (MEDI4736) in Kombination mit neuartigen onkologischen Therapien mit oder ohne Paclitaxel für metastasierende Dreifach-Erstlinien Negativ Brustkrebs
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.
Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 5L3
- Research Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 4L6
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Kanada, J4V 2H1
- Research Site
-
Montreal, Quebec, Kanada, H4A 3J1
- Research Site
-
-
-
-
-
Gdansk, Polen, 80-952
- Research Site
-
Krakow, Polen, 31-501
- Research Site
-
Lublin, Polen, 20-090
- Research Site
-
Opole, Polen, 45-060
- Research Site
-
Rzeszów, Polen, 35-021
- Research Site
-
Warsaw, Polen, 02-781
- Research Site
-
Warsaw, Polen, 04-141
- Research Site
-
-
-
-
-
Seoul, Südkorea, 03080
- Research Site
-
Seoul, Südkorea, 05505
- Research Site
-
Seoul, Südkorea, 06351
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taichung, Taiwan, 40447
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85715
- Research Site
-
-
Maryland
-
Columbia, Maryland, Vereinigte Staaten, 21044
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Research Site
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Research Site
-
-
Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Research Site
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Research Site
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
- Research Site
-
-
Virginia
-
Williamsburg, Virginia, Vereinigte Staaten, 23188
- Research Site
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Research Site
-
London, Vereinigtes Königreich, EC1M 6BQ
- Research Site
-
Manchester, Vereinigtes Königreich, M20 4BX
- Research Site
-
Oxford, Vereinigtes Königreich, OX3 7LE
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria
- Female
- At least 18 years of age at the time of screening
- Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
- No prior treatment for metastatic (Stage IV) TNBC
- Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
- WHO/ECOG status at 0 or 1 at enrollment
Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)
Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay
Exclusion criteria
- History of allogeneic organ transplantation
- Active or prior documented autoimmune or inflammatory disorders
- Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
- Untreated CNS metastases
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
- Female patients who are pregnant, breastfeeding
- Cardiac Ejection Fraction less than 50%
Patients enrolled in Arm 2 only:
- Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
- Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
- Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months
Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.
Patients enrolled in Arm 6, 7 and 8 only:
- History of or active interstitial lung disease/pneumonitis
- Use of chloroquine or hydroxychloroquine in <14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
- Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Arm 1
durvalumab + paclitaxel |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off |
|
Experimental: Arm 2
durvalumab + paclitaxel + capivasertib |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
Andere Namen:
|
|
Experimental: Arm 5
durvalumab + paclitaxel + oleclumab |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
Andere Namen:
|
|
Experimental: Arm 6
durvalumab + trastuzumab deruxtecan |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Andere Namen:
|
|
Experimental: Arm 7
durvalumab + datopotamab deruxtecan |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Andere Namen:
|
|
Experimental: Arm 8
durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status) |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Andere Namen:
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Dose Limiting Toxicity (DLT) Events
Zeitfenster: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
|
The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients |
From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR)
Zeitfenster: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR. |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Progression-free Survival (PFS)
Zeitfenster: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression) |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Duration of Response (DoR)
Zeitfenster: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Overall Survival (Count)
Zeitfenster: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
Number of patients with overall survival, the time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause |
From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
|
Overall Survival (Duration)
Zeitfenster: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause |
From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
|
Progression-free Survival at 6 Months (PFS6)
Zeitfenster: 6 months following date of first dose
|
Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) |
6 months following date of first dose
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Peter Schmid, MD, PhD, Barts Cancer Institute
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Hautkrankheiten
- Brusterkrankungen
- Haut- und Bindegewebserkrankungen
- Neoplasien der Brust
- Dreifach negative Brustneoplasmen
- Organische Chemikalien
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Taxoid
- Cyclodececane
- Diterpene
- Paclitaxel
- Capivasertib
- Durvalumab
- Trastuzumab Deruxtcan
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- D933LC00001
- 2018 (US NIH Stipendium/Vertrag)
- 2018-000764-29 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .